Hepion Pharmaceuticals In... (HEPA)
NASDAQ: HEPA
· Real-Time Price · USD
0.29
0.00 (0.21%)
At close: May 01, 2025, 3:52 PM
0.21% (1D)
| Bid | 0.29 |
| Market Cap | 3.16M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -13.19M |
| EPS (ttm) | -5367.5 |
| PE Ratio (ttm) | n/a |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 0.29 |
| Volume | 673,057 |
| Avg. Volume (20D) | 3,997,562 |
| Open | 0.28 |
| Previous Close | 0.29 |
| Day's Range | 0.28 - 0.30 |
| 52-Week Range | 0.25 - 79.50 |
| Beta | 1.80 |
About HEPA
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in clinical-phase development for the treatment of non-alcoholic steatohepatitis (NASH...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 10, 2014
Employees 22
Stock Exchange NASDAQ
Ticker Symbol HEPA
Website https://www.hepionpharma.com
1 month ago
-39.15%
Hepion Pharmaceuticals shares are trading lower af...
Unlock content with
Pro Subscription
3 months ago
-58.05%
Hepion Pharmaceuticals shares are trading lower after the company announced a $9 million public offering.
